Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for sec...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood advances Jg. 4; H. 19; S. 4898 - 4911
Hauptverfasser:	Locke, Frederick L., Rossi, John M., Neelapu, Sattva S., Jacobson, Caron A., Miklos, David B., Ghobadi, Armin, Oluwole, Olalekan O., Reagan, Patrick M., Lekakis, Lazaros J., Lin, Yi, Sherman, Marika, Better, Marc, Go, William Y., Wiezorek, Jeffrey S., Xue, Allen, Bot, Adrian
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Inc 13.10.2020 American Society of Hematology
Schlagworte:	Antigens, CD19 - therapeutic use Humans Immunobiology and Immunotherapy Immunotherapy, Adoptive Inflammation Tumor Burden
ISSN:	2473-9529, 2473-9537, 2473-9537
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!